RDAF welcomes new board members in 2019

    26 Mar, 2019

    In March 2019, the General Assembly of the Rare Disease Action Forum (RDAF) elected the Forum’s board, welcoming two new board members: Dr. Pierre Morneau, General Manager at Takeda Switzerland and Dr. Saskia Karg, Project Lead Rare Diseases at the University Children’s Hospital Zürich.

    The two new board members succeed Ms Rute Fernandes, General Manager at Takeda Switzerland and Matthias Heck, Director Global Value, Access and Policy at Alexion who did not run for reelection. The secretariat would like to thank Rute Fernandes and Matthias Heck for the considerable expertise and great contributions made as a board members of the RDAF. The new board composition reaffirms the multistakeholder approach of the Forum. The RDAF is looking forward to continuing its efforts to facilitate the development of sustainable solutions that improve the situation of patients with rare diseases in Switzerland.

    Continue reading

    Boehringer Ingelheim joins the Rare Disease Action Forum

    We are delighted to announce Boehringer Ingelheim as new member of the Rare Disease Action Forum. Boehringer Ingelheim’s membership fortifies RDAF's multi-stakeholder base, alongside other members from industry, patient organizations, healthcare professionals, and...